首页> 外文期刊>mSphere >Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027
【24h】

Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027

机译:设计的艰难梭菌027型TcdB锚蛋白重复蛋白(DARPin)中和剂

获取原文
           

摘要

Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea. In recent decades, the emergence of the “hypervirulent” BI/NAP1/027 strains of C. difficile significantly increased the morbidity and mortality of CDI. The pathogenesis of CDI is primarily mediated by the action of two toxins, TcdA and TcdB, with TcdB being the major virulent factor in humans. In this report, we describe the engineering of a panel of designed ankyrin repeat proteins (DARPins) that potently neutralize TcdB from the BI/NAP1/027 strains (e.g., TcdBsubUK1/sub). The most effective DARPin, D16, inhibits TcdBsubUK1/sub with a 50% effective concentration (ECsub50/sub) of 0.5?nM, which is 66-fold lower than that of the FDA-approved anti-TcdB antibody bezlotoxumab (ECsub50/sub, ~33?nM). Competitive enzyme-linked immunosorbent assays (ELISAs) showed that D16 blocks interactions between TcdB and its receptor, chondroitin sulfate proteoglycan 4 (CSPG4). The dimeric DARPin U3D16, which pairs D16 with DARPin U3, a disrupter of the interaction of TcdB with Frizzled 1/2/7 receptor, exhibits 10-fold-to-20-fold-enhanced neutralization potency against TcdB from C. difficile strains VPI 10463 (laboratory strain) and M68 (CF/NAP9/017) but identical activity against TcdBsubUK1/sub relative to D16. Subsequent ELISAs revealed that TcdBsubUK1/sub did not significantly interact with Frizzled 1/2/7. Computation modeling revealed 4?key differences at the Frizzled 1/2/7 binding interface which are likely responsible for the significantly reduced binding affinity. IMPORTANCE We report the engineering and characterization of designed ankyrin proteins as potent neutralizers of TcdB toxin secreted by a hypervirulent ribotype 027 strain of Clostridium difficile . We further show that although TcdB toxins from both ribotype 027 and VPI 10461 interact efficiently with TcdB receptors CSPG4 and Pvrl3, TcdBsub027/sub lacks significant ability to bind the only known physiologically relevant TcdB receptor, Frizzled 1/2/7.
机译:艰难梭菌感染(CDI)是医院获得性腹泻的主要原因。在最近的几十年中,艰难梭菌的“高毒力” BI / NAP1 / 027菌株的出现显着增加了CDI的发病率和死亡率。 CDI的发病机理主要是由两种毒素TcdA和TcdB的作用介导的,其中TcdB是人类的主要毒性因子。在此报告中,我们描述了一组设计的锚蛋白重复蛋白(DARPins)的工程设计,该蛋白可有效中和BI / NAP1 / 027菌株中的TcdB(例如TcdB UK1 )。最有效的DARPin D16以0.5?nM的50%有效浓度(EC 50 )抑制TcdB UK1 ,比其低66倍。 FDA批准的抗TcdB抗体贝洛酮单抗(EC 50 ,〜33?nM)。竞争性酶联免疫吸附测定(ELISA)表明,D16阻断TcdB及其受体硫酸软骨素蛋白聚糖4(CSPG4)之间的相互作用。 DARPin U3D16二聚体与DARPin U3配对,DARPin U3是TcdB与卷曲的1/2/7受体相互作用的破坏剂,对艰难梭菌VPI的TcdB表现出增强的10倍至20倍的中和力。 10463(实验室菌株)和M68(CF / NAP9 / 017),但相对于D16,其对TcdB UK1 的活性相同。随后的酶联免疫吸附测定表明,TcdB UK1 与卷曲的1/2/7没有明显的相互作用。计算模型表明,在卷曲的1/2/7结合界面有4个关键的差异,这可能是导致结合亲和力显着降低的原因。重要我们报道了工程锚蛋白的工程化和表征,作为艰难梭菌027型高毒力菌株分泌的TcdB毒素的中和剂。我们进一步表明,尽管来自ribbotype 027和VPI 10461的TcdB毒素与TcdB受体CSPG4和Pvrl3有效相互作用,但TcdB 027 缺乏结合唯一已知的生理相关TcdB受体Frizzled 1/2 /的显着能力。 7。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号